Affinity offers a computational platform that accelerates drug discovery by streamlining hit prioritization and decision-making for medicinal chemists. Its advanced analytics and interactive visualization tools enable efficient identification of promising drug candidates, reducing cycle times and expanding research focus.
Funding
Funding not disclosed
Founders
Product
Problem
Medicinal chemists face significant time and cost constraints when screening large compound libraries, often leading to a narrowed research focus and delayed drug discovery timelines. Manual analysis of screening data and reliance on traditional in silico tools can also hinder efficient hit prioritization and decision-making.
Solution
Affinity provides an advanced computational platform designed to accelerate hit prioritization and enhance decision-making for medicinal chemists. The platform streamlines the drug discovery workflow by offering sophisticated analytics and interactive visualization tools. This enables researchers to identify and select promising drug candidates with increased accuracy and reduced cycle times. By automating key aspects of the screening and analysis process, Affinity allows chemists to dedicate more resources to complex research challenges and explore a broader range of therapeutic avenues.
Target Audience
The primary users are medicinal chemists and drug discovery teams within pharmaceutical companies and biotechnology firms.
Features
- High-throughput virtual screening capabilities for millions of compounds.
- Advanced analytics suite for quantitative assessment of compound properties and predicted efficacy.
- Interactive visualization tools for intuitive exploration of screening results and structure-activity relationships (SAR).
- Machine learning models for predictive compound profiling and hit-to-lead optimization.
- Streamlined data integration from various screening and assay platforms.
- User-friendly interface designed for medicinal chemists with minimal computational chemistry expertise.